|
|
If this email does not display correctly, click here
|
|
|
|
|
|
|
|
Newsletter #136 September 27th, 2018
|
|
|
|
|
|
|
|
Editorial
Dear Friends,
Our newsletter begins with an article by Paul Enck about how fecal microbiota transfer in Clostridium difficile infections may remain a reminiscent therapy that has its empirical justification, until it is replaced by something equally or more effective. You will then find a post reviewing a new, open access paper by ISAPP that provides robust evidence regarding the specific health benefits of probiotics in humans.
Next comes a mice study that has shown for the first time the direct mechanism used by the gut microbiota via microbial metabolites to defend the host against the well known enteric pathogen Salmonella. Finally, you can read up on a study that contributes to a better understanding of the role of immunoglobulin A (IgA) on gut homeostasis.
The GMFH publishing team
|
|
|
|
|
|
|
|
|
|
New ISAPP Paper: Probiotics for Human Use
Looking for a review that covers all the bases of probiotic health effects? A new, open access paper may serve that purpose. “Probiotics for human use” is a peer-reviewed paper published by the Nutrition Bulletin. This was a collaborative effort by...
|
|
|
|
|
|
|
|
|
|
|
|
|
©2018 Gut Microbiota For Health
If you need further information send us an email to contact@gutmicrobiotaforhealth.com
You have received this e-mail because you have shown an interest in receiving news from us. If you don’t want to continue receiving information from us, please unsubscribe
www.gutmicrobiotaforhealth.com is edited by
|
|
|
|
|
|
|
|
|
|
Before print this message, please check that it is really necessary
|
|
|